This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line pediatric-like protocol in Argentina.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluate event free survival of AYA Ph-negative ALL patients treating in first line depending on risk category.
Timeframe: 36 months
Evaluate overall survival of AYA Ph-negative ALL patients treating in first line depending on risk category.
Timeframe: 36 months
Evaluate toxicities of AYA Ph-negative ALL patients treating in first line depending on risk category.
Timeframe: 36 months